Reassessment of the role of induction chemotherapy for head and neck cancer

Michael K. Gibson, Arlene A. Forastiere

Research output: Contribution to journalArticle

Abstract

Head and neck cancers are a complex group of diseases defined by variations in histological features, anatomical location, and cause. Once the realm of surgeons and radiation oncologists, the treatment of locally advanced disease now involves medical oncologists. Major developments include primary chemoradiotherapy for unresectable disease and organ preservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radiation techniques, and biological therapies. Concomitant chemoradiotherapy consistently improves locoregional control. However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence. Given this shift in site of recurrence, therapeutic strategies to suppress distant metastases may be the next goal for further improvement of survival. One approach that merits reassessment is the use of induction chemotherapy in the setting of locally advanced disease-both resectable and unresectable. In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.

Original languageEnglish (US)
Pages (from-to)565-574
Number of pages10
JournalThe Lancet Oncology
Volume7
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Induction Chemotherapy
Head and Neck Neoplasms
Chemoradiotherapy
Neoplasm Metastasis
Organ Preservation
Recurrence
Adjuvant Radiotherapy
Biological Therapy
Radiotherapy
Clinical Trials
Drug Therapy
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Reassessment of the role of induction chemotherapy for head and neck cancer. / Gibson, Michael K.; Forastiere, Arlene A.

In: The Lancet Oncology, Vol. 7, No. 7, 07.2006, p. 565-574.

Research output: Contribution to journalArticle

@article{efc2b005281b4dda82f623659bcca0ed,
title = "Reassessment of the role of induction chemotherapy for head and neck cancer",
abstract = "Head and neck cancers are a complex group of diseases defined by variations in histological features, anatomical location, and cause. Once the realm of surgeons and radiation oncologists, the treatment of locally advanced disease now involves medical oncologists. Major developments include primary chemoradiotherapy for unresectable disease and organ preservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radiation techniques, and biological therapies. Concomitant chemoradiotherapy consistently improves locoregional control. However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence. Given this shift in site of recurrence, therapeutic strategies to suppress distant metastases may be the next goal for further improvement of survival. One approach that merits reassessment is the use of induction chemotherapy in the setting of locally advanced disease-both resectable and unresectable. In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.",
author = "Gibson, {Michael K.} and Forastiere, {Arlene A.}",
year = "2006",
month = "7",
doi = "10.1016/S1470-2045(06)70757-4",
language = "English (US)",
volume = "7",
pages = "565--574",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "7",

}

TY - JOUR

T1 - Reassessment of the role of induction chemotherapy for head and neck cancer

AU - Gibson, Michael K.

AU - Forastiere, Arlene A.

PY - 2006/7

Y1 - 2006/7

N2 - Head and neck cancers are a complex group of diseases defined by variations in histological features, anatomical location, and cause. Once the realm of surgeons and radiation oncologists, the treatment of locally advanced disease now involves medical oncologists. Major developments include primary chemoradiotherapy for unresectable disease and organ preservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radiation techniques, and biological therapies. Concomitant chemoradiotherapy consistently improves locoregional control. However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence. Given this shift in site of recurrence, therapeutic strategies to suppress distant metastases may be the next goal for further improvement of survival. One approach that merits reassessment is the use of induction chemotherapy in the setting of locally advanced disease-both resectable and unresectable. In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.

AB - Head and neck cancers are a complex group of diseases defined by variations in histological features, anatomical location, and cause. Once the realm of surgeons and radiation oncologists, the treatment of locally advanced disease now involves medical oncologists. Major developments include primary chemoradiotherapy for unresectable disease and organ preservation, the addition of chemotherapy to adjuvant radiotherapy, improvement in surgical and radiation techniques, and biological therapies. Concomitant chemoradiotherapy consistently improves locoregional control. However, control of distant metastases is poor, resulting in an increasing proportion of deaths from systemic recurrence. Given this shift in site of recurrence, therapeutic strategies to suppress distant metastases may be the next goal for further improvement of survival. One approach that merits reassessment is the use of induction chemotherapy in the setting of locally advanced disease-both resectable and unresectable. In this review we summarise data for the use of induction chemotherapy to define better which patients will likely benefit from this approach now and which questions are important in the design of future clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=33745268219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745268219&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(06)70757-4

DO - 10.1016/S1470-2045(06)70757-4

M3 - Article

C2 - 16814208

AN - SCOPUS:33745268219

VL - 7

SP - 565

EP - 574

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 7

ER -